(2,2-diphenyl-[1,3]oxathiolan-5-ylmethyl)-(3-phenyl-propyl)-amine: A Potent and Selective 5-HT1A receptor agonist

ChemMedChem

Volumn 4, Issue 2, 2009, Pages 196-203

  Franchini, Silvia ^a   Tait, Annalisa ^a   Prandi, Adolfo ^a   Sorbi, Claudia ^a   Gallesi, Rossella ^a   Buccioni, Michela ^b   Marucci, Gabriella ^b   De Stefani, Carla ^c   Cilia, Antonio ^c   Brasili, Livio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c Recordati SpA   (Italy)

Author keywords

5 HT1a; Biological activity; Drug design; Receptors; Structure activity relationships

Indexed keywords

(2 PHENOXYETHYL)[2 (5H DIBENZO[A,D]CYCLOHEPTEN 5 YL)[1,3]DIOXOLAN 4 YLMETHYL]AMINE; (2 PHENOXYETHYL)[2 (9H FLUOREN 9 YL)[1,3]DIOXOLAN 4 YLMETHYL]AMINE; (2 PHENOXYETHYL)[2 [10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YL][1,3]DIOXOLAN 4 YLMETHYL]AMINE; (2,2 DIPHENYL[1,3]DIOXOLAN 4 YLMETHYL)(2 PHENYLSULFANYLETHYL)AMINE; (2,2 DIPHENYL[1,3]DIOXOLAN 4 YLMETHYL)(3 PHENYLPROPYL)AMINE; (2,2 DIPHENYL[1,3]DIOXOLAN 4 YLMETHYL)(4 PHENYLBUTYL)AMINE; (2,2 DIPHENYL[1,3]DIOXOLAN 4 YLMETHYL)[2 (NAPHTHALEN 1 YLOXY) ETHYL]AMINE; (2,2 DIPHENYL[1,3]DIOXOLAN 4 YLMETHYL)[2 (NAPHTHALEN 2 YLOXY) ETHYL]AMINE; (2,2 DIPHENYL[1,3]DIOXOLAN 4 YLMETHYL)PHENETHYLAMINE; (2,2 DIPHENYL[1,3]DITHIOLAN 4 YLMETHYL)(3 PHENYLPROPYL)AMINE; (2,2 DIPHENYL[1,3]OXATHIOLAN 5 YLMETHYL)(3 PHENYLPROPYL)AMINE; 2 (2,2 DIPHENYL[1,3]DIOXOLAN 4 YL)ETHANOL; 2 BENZHYDRYL 4 (2 CHLOROETHYL) (1,3)DIOXOLANE; 2 BENZHYDRYL 4 (2 CHLOROETHYL)[1,3]DIOXOLANE; 4 (2 CHOROETHYL) 4 (2 CHLOROETHYL) (1,3)DIOXOLANE; 4 (CHLOROETHYL) 2,2 DIPHENYL[1,3]DIOXOLANE; 4' (CHLOROMETHYL)SPIRO[5H DIBENZO[A,D]CYLCOHEPTEN 5,2' [1,3]DIOXOLANE]; [2 (2,2 DIPHENYL[1,3]DIOXOLAN 4 YL)ETHYL](3 PHENYLPROPYL)AMINE; BENZYL(2,2 DIPHENYL[1,3]DIOXOLAN 4 YLMETHYL)AMINE; N (2,2 DIPHENYL[1,3]DIOXOLAN 4 YLMETHYL) N' PHENYLETHANE 1,2 DIAMINE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; AORTA; HELA CELLS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATE; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 60849119274     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200800276     Document Type: Article

References (25)

1. Serotoninergic Neurons and 5-HT Receptors in the CNS (Eds.: H. G. Baumgarten, M. Göthert), Springer Verlag, Berlin, 1997.
2. D. Hoyer, G. Martin, Neuropharmacology 1997, 36, 419-428.
3. Serotonin Receptors and their Ligands (Eds.: B. Olivier, I. van Wijngaarden, W. Soudijn), Elsevier, Amsterdam, 1997.
4. G. Caliendo, V. Santagada, E. Perissutti, F. Fiorino, Curr. Med. Chem. 2005, 12, 1721-1753.
5. 1A= Receptors in Depression and Anxiety (Eds.: S. M. Stahl, M. Gastpar, J. M. Keppel-Hesse-link, J. Traber), Raven, New York, 1992, pp. 55-81.
6. J. De Vry, Psychopharmacology 1995, 121, 1-26.
7. L. E. Gonzalez, S. E. File, D. H. Overstreet, Pharmacol. Biochem. Behav. 1998, 59, 787-792.
8. D. Gurwitz, Drug Discovery Today 1999, 4, 142-143.
9. A. C. Berends, P. G. M. Luiten, C. Nyakas, CNS Drug Rev. 2005, 11, 379-402.
10. F. C. Colpaert, Curr. Opin. Invest. Drugs 2006, 7, 40-47.
11. L. E. Schechter, D. L. Smith, S. Rosenzweig-Lipson, S.J. Sukoff, L. A. Dawson, K. Marquis, D. Jones, M. Piesla, T. Andree, S. Nawoschik, J. A. Harder, M. D. Womack, J. Buccafusco, A. V. Terry, B. Hoebel, P. Rada, M. Kelly, M. Abou-Gharbia, J. E. Barrett, W. Childers, J. Pharm. Exp. Ther. 2005, 314, 1274-1289.
12. S. Trumpp-Kallmeyer, J. Hoflack, A. Bruinvels, M. Hibert, J. Med. Chem. 1992, 35, 3448-3462.
13. L. Brasili, C. Sorbi, S. Franchini, M. Manicardi, P. Angeli, G. Marucci, A. Leonardi, E. Poggesi, J. Med. Chem. 2003, 46, 1504-1511.
14. M. Pigini, L. Brasili, M. Giannella, D. Giardina, U. Gulini, W. Quaglia, C. Melchiorre, J. Med. Chem. 1988, 31, 2300-2304.
15. M. Eltze, R. Boer, K. H. Sanders, N. Kolassa, Eur. J. Pharmacol. 1991, 202, 33-44.
16. F. N. Ko, J. H. Guh, S. M. Yu, Y. S. Hou, Y. C. Wu, C. M. Teng, Br. J. Pharmacol. 1994, 112, 1174-1180.
17. S. A. Buckner, K. W. Oheim, P. A. Morse, S. M. Knepper, A. A. Hancock, Eur. J. Pharmacol. 1996, 297, 241-248.
18. R. Testa, C. Taddei, E. Poggesi, C. Destefani, S. Cotecchia, J. P. Hieble, A. C. Sulpizio, D. Naselsky, D. Bergsma, S. Ellis, A. Swift, S. Ganguly, R. R. Ruffolo, A. Leonardi, Pharmacol. Commun. 1995, 6, 79-86.
19. R. Testa, L. Guarneri, E. Poggesi, P. Angelico, C. Velasco, M. Ibba, A. Cilia, G. Motta, C. Riva, A. Leonardi, J. Pharmacol. Exp. Ther. 1999, 290, 1258-1269.
20. P. Angeli, M. Giannella, M. Pigini, F. Gualtieri, E. Teodori, B. Valsecchi, G. Gaviraghi, Eur. J. Med. Chem. 1985, 20, 517-523.
21. G. Zólyomi, F. Sirokmán, G. Toth, I. Elekes, J. Labelled Compd. Radiopharm. 1982, 19, 247-255.
22. J. A. Stanton, M. S. Bee, Eur. J. Pharmacol. 1997, 320, 267-275.
23. J. M. van Rossum, Arch. Int. Pharmacodyn. Ther. 1963, 143, 299-330.
24. A. De Lean, P. J. Munson, D. Rodbar, Am. J. Physiol. 1978, 235, E97-E102.
25. Y. C. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099-3108.